Endogenous secretory receptor for advanced glycation end-products and cardiovascular disease in end-stage renal disease.
Endogenous secretory receptor for advanced glycation end-products and cardiovascular disease in end-stage renal disease.
复制标题
晚期糖基化终产物和终末期肾病心血管疾病的内源性分泌受体。
DOI：
10.1053/j.jrn.2007.10.016
复制
发表时间：
2008
期刊：
影响因子：
--
通讯作者：
H. Koyama
中科院分区：
文献类型：
--
作者：
Y. Nishizawà;H. Koyama
晚期糖基化终产物 (RAGE) 受体与糖尿病的微血管和大血管并发症有关。糖尿病动物动脉粥样硬化斑块中RAGE表达上调，糖尿病小鼠动脉粥样硬化的加剧受到RAGE竞争的抑制。内源性分泌型 RAGE (esRAGE) 被鉴定为一种新型剪接变体，携带所有胞外结构域，但缺乏跨膜和胞质内结构域。 esRAGE从细胞中释放出来，与晚期糖基化终产物结合，这能够中和晚期糖基化终产物对培养物内皮细胞的作用。 esRAGE的腺病毒过度表达可恢复糖尿病血管功能障碍的损伤，表明esRAGE可能是体内RAGE信号传导的重要抑制剂，并可能有助于预防糖尿病血管并发症。在 203 名年龄和性别匹配的 2 型糖尿病受试者和 134 名非糖尿病受试者中，血浆 esRAGE 水平与颈动脉或股动脉粥样硬化呈负相关。终末期肾病 (ESRD) 患者的血浆 esRAGE 水平高于无 ESRD 患者。在对 206 名慢性肾功能衰竭患者（包括 171 名非糖尿病患者）进行中位随访 111 个月的队列中，根据 Kaplan-Meier 估计，血浆 esRAGE 最低三分位受试者的心血管死亡累积发生率显着高于中间或最高三分位受试者。与血浆 esRAGE 的最低三分位数相比，最高和中间三分位数的风险比分别为 0.40（95% 置信区间，0.18 至 0.89）和 0.26（95% 置信区间，0.10 至 0.66）。即使在调整体重指数、高血压、血脂异常和血管并发症后，esRAGE 较低水平的较高风险仍然显着，并且仅与年龄和糖尿病混淆。因此，我们假设血浆 esRAGE 是一种潜在的保护因子，也是一种针对 ESRD 心血管疾病发生的新型生物标志物。
The receptor for advanced glycation end-products (RAGE) is involved in microvascular and macrovascular complications in diabetes. The expression of RAGE is up-regulated in atherosclerotic plaques of diabetic animals, and the augmentation of atherosclerosis in diabetic mice is inhibited by the competition of RAGE. An endogenous secretory RAGE (esRAGE) was identified as a novel splice variant carrying all of the extracellular domains, but devoid of the transmembrane and intracytoplasmic domains. The esRAGE is released from the cells, to bind advanced glycation end-products, and this is capable of neutralizing the actions of advanced glycation end-products on endothelial cells in culture. The adenoviral overexpression of esRAGE restores the impairment of vascular dysfunction in diabetes, suggesting that esRAGE may be an important inhibitor of RAGE signaling in vivo, and may be useful for the prevention of diabetic vascular complications. In 203 age-matched and sex-matched type 2 diabetic and 134 nondiabetic subjects, plasma esRAGE levels were inversely associated with carotid or femoral atherosclerosis. In patients with end-stage renal disease (ESRD), plasma esRAGE levels are higher than in those without ESRD. In a cohort of 206 patients (including 171 nondiabetic patients) with chronic renal failure who were followed for a median of 111 months, the cumulative incidence of cardiovascular death by Kaplan-Meier estimation was significantly higher in subjects in the lowest tertile of plasma esRAGE than in those in the middle or highest tertile. Compared with the lowest tertile of plasma esRAGE, the hazards ratios for the highest and middle tertile were 0.40 (95% confidence interval, 0.18 to 0.89) and 0.26 (95% confidence interval, 0.10 to 0.66), respectively. The higher risk at the lower level of esRAGE was still significant even after adjustment for body mass index, hypertension, dyslipidemia, and vascular complications, and was confounded only by age and diabetes. Thus, we postulate that plasma esRAGE is a potential protective factor and a novel biomarker against the occurrence of cardiovascular disease in ESRD.
登录
查看更多内容
影响因子：
15.9
作者：
Mizutani, M;Kern, TS;Lorenzi, M
通讯作者：
Lorenzi, M
影响因子：
15.9
作者：
SCHMIDT, AM;HORI, O;STERN, D
通讯作者：
STERN, D
影响因子：
4.8
作者：
Vincent, Andrea M.;Perrone, Lorena;Feldman, Eva L.
通讯作者：
Feldman, Eva L.
DOI：
10.1016/s0021-9258(18)42138-2
发表时间：
1992-07
期刊：
The Journal of biological chemistry
影响因子：
--
作者：
M. Neeper;A. Schmidt;J. Brett;S. Yan;F. Wang;Y. C. Pan;Keith Owen Elliston;D. Stern;A. Shaw
通讯作者：
M. Neeper;A. Schmidt;J. Brett;S. Yan;F. Wang;Y. C. Pan;Keith Owen Elliston;D. Stern;A. Shaw
影响因子：
15.9
作者：
Schmidt, AM;Du Yan, S;Stern, DM
通讯作者：
Stern, DM